GlassScriptPhysician profile
William Schneider
NPI 1023273109
$19,620.78
in general payments reported to CMS, 2019-2025
19 companies · $1,564 in 2025
The $1,564 reported for 2025 was more than what 93% of Forensic Psychiatry providers received nationally (typical 2025 total: $125).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $240 · 2020: $6,413 · 2021: $7,944 · 2022: $1,773 · 2023: $530 · 2024: $1,156 · 2025: $1,564.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,250.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $15,497.15 | 2020-2025 | Abilify Maintena, Abilify Asimtufii, Rexulti |
| Alkermes, INC. | $833.85 | 2019-2025 | Aristada, Lybalvi |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $651.75 | 2021-2025 | Caplyta |
| Neurocrine Biosciences, INC. | $496.29 | 2023-2025 | Ingrezza |
| Abbvie INC. | $402.71 | 2024-2025 | |
| Supernus Pharmaceuticals, INC. | $356.94 | 2024-2025 | Qelbree |
| Sunovion Pharmaceuticals INC. | $273.61 | 2020-2022 | |
| Janssen Pharmaceuticals, INC | $189.75 | 2022-2025 | Invega Sustenna, Invega Trinza, Spravato |
| Vanda Pharmaceuticals INC. | $174.85 | 2025 | Fanapt |
| Teva Pharmaceuticals USA, INC. | $158.51 | 2022-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Lundbeck LLC | $153.44 | 2023-2024 | Rexulti, Abilify Maintena |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $115.40 | 2021 | |
| Ironshore Pharmaceuticals INC. | $82.18 | 2024 | |
| Corium, LLC | $82.07 | 2024-2025 | Azstarys |
| Collegium Pharmaceutical, INC. | $62.19 | 2025 | Jornay Pm |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $38.89 | 2025 | Cobenfy |
| Tris Pharma INC | $19.98 | 2025 | Dyanavel Xr |
| Takeda Pharmaceuticals U.S.A., INC. | $16.26 | 2025 | Trintellix |
| Vertical Pharmaceuticals, LLC | $14.96 | 2025 | Relexxii |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Schneider listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.